JP2023533937A5 - - Google Patents

Info

Publication number
JP2023533937A5
JP2023533937A5 JP2023500008A JP2023500008A JP2023533937A5 JP 2023533937 A5 JP2023533937 A5 JP 2023533937A5 JP 2023500008 A JP2023500008 A JP 2023500008A JP 2023500008 A JP2023500008 A JP 2023500008A JP 2023533937 A5 JP2023533937 A5 JP 2023533937A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
antibody
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/067855 external-priority patent/WO2022002940A1/en
Publication of JP2023533937A publication Critical patent/JP2023533937A/ja
Publication of JP2023533937A5 publication Critical patent/JP2023533937A5/ja
Priority to JP2026010946A priority Critical patent/JP2026082887A/ja
Pending legal-status Critical Current

Links

JP2023500008A 2020-06-29 2021-06-29 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 Pending JP2023533937A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026010946A JP2026082887A (ja) 2020-06-29 2026-01-27 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063045448P 2020-06-29 2020-06-29
US63/045,448 2020-06-29
US202063094571P 2020-10-21 2020-10-21
US63/094,571 2020-10-21
PCT/EP2021/067855 WO2022002940A1 (en) 2020-06-29 2021-06-29 Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026010946A Division JP2026082887A (ja) 2020-06-29 2026-01-27 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2023533937A JP2023533937A (ja) 2023-08-07
JP2023533937A5 true JP2023533937A5 (cg-RX-API-DMAC7.html) 2024-06-19

Family

ID=76744843

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023500008A Pending JP2023533937A (ja) 2020-06-29 2021-06-29 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用
JP2026010946A Pending JP2026082887A (ja) 2020-06-29 2026-01-27 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026010946A Pending JP2026082887A (ja) 2020-06-29 2026-01-27 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用

Country Status (12)

Country Link
US (1) US20230263902A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171652A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023533937A (cg-RX-API-DMAC7.html)
KR (1) KR20230028492A (cg-RX-API-DMAC7.html)
CN (1) CN116322787A (cg-RX-API-DMAC7.html)
AU (1) AU2021299947A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025105A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183898A1 (cg-RX-API-DMAC7.html)
IL (1) IL299334A (cg-RX-API-DMAC7.html)
MX (1) MX2022015375A (cg-RX-API-DMAC7.html)
TW (1) TW202216210A (cg-RX-API-DMAC7.html)
WO (1) WO2022002940A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー/エス 抗pd-1抗体と抗組織因子抗体-薬物コンジュゲートとの組み合わせを用いるがんの治療方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
PE20221004A1 (es) * 2019-07-03 2022-06-15 Iconic Therapeutics Inc Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル.エル.シー. Hco32およびhco27、ならびに関連実施例
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
SI3071237T1 (sl) 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
BR112020008593A2 (pt) * 2017-11-02 2020-10-20 Genmab A/S método de tratamento de câncer cervical em um indivíduo

Similar Documents

Publication Publication Date Title
Lee et al. An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3021)
Ricci et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study
JP2025020147A5 (cg-RX-API-DMAC7.html)
Kornek et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer
Hwang et al. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
KR102943054B1 (ko) 면역 체크포인트 저해약 및 폴피리녹스 요법과의 병용에 의한 암 치료
JP2012509889A5 (cg-RX-API-DMAC7.html)
ten Tije et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
DK2656844T3 (en) ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
JP2003533485A5 (cg-RX-API-DMAC7.html)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2021528496A5 (cg-RX-API-DMAC7.html)
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
TW201127384A (en) Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
JP2016515619A5 (cg-RX-API-DMAC7.html)
CA2902144A1 (en) Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
CN1674908A (zh) erb B激酶抑制剂和抗肿瘤疗法的联合治疗
JP2024539476A (ja) 医薬組成物およびその使用
JP2025163103A (ja) 放射線および/または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
CN115461079A (zh) 用于治疗肾癌的联用药物
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
Iwase et al. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer
JP2005511663A5 (cg-RX-API-DMAC7.html)
JP2005511663A (ja) 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用
Basha et al. A review on chemotherapy induced complications in cancer patients